Nuvectis Pharma (NVCT) Profit After Tax (2021 - 2026)

Nuvectis Pharma (NVCT) has 6 years of Profit After Tax data on file, last reported at -$6.0 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 13.47% year-over-year to -$6.0 million; the trailing twelve-month figure through Mar 2026 stood at -$27.2 million (down 34.72% YoY), and the FY2025 full-year result was -$26.4 million, down 39.17% from the prior year.
• Profit After Tax improved to -$6.0 million in Q1 2026, from -$7.3 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$2.9 million in Q1 2022 to a low of -$7.5 million in Q3 2025.
• A 5-year average of -$5.5 million and a median of -$5.9 million in 2022 frame the typical range for Profit After Tax.
• Peak annual rise in Profit After Tax reached 39.9% in 2022, while the deepest fall reached 196.15% in 2022.
• Tracing NVCT's Profit After Tax over 5 years: stood at -$6.7 million in 2022, then rose by 1.11% to -$6.6 million in 2023, then climbed by 5.65% to -$6.2 million in 2024, then retreated by 17.06% to -$7.3 million in 2025, then grew by 17.28% to -$6.0 million in 2026.
• Business Quant data shows NVCT's Profit After Tax at -$6.0 million in Q1 2026, -$7.3 million in Q4 2025, and -$7.5 million in Q3 2025.